SLC16A1 and cancer: Our data are consistent with those of other studies in patients with advanced cancer showing that MCT1 inhibition may have a significant effect on cancer growth and progression and may represent a druggable target for the development of new therapeutic strategies [ClinicalTrials.gov identifier (NCT number): NCT01791595].